首頁 > 市場調查報告書 > 製藥

動物用醫藥

市場調查報告書

商品編碼

1800258

全球獸醫與人類藥品市場：2025-2030 年預測

Global Human Drugs for Veterinary Use Market - Forecasts fom 2025 to 2030

出版日期: 2025年08月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

獸用人類藥品市場預計將從 2025 年的 37.04 億美元成長到 2030 年的 42.4 億美元，複合年成長率為 2.74%。

預計 2025 年至 2030 年，獸用人藥市場將經歷強勁成長，這主要得益於動物慢性病患病率上升、寵物擁有量增加以及將動物用藥品的趨勢日益成長。由於對動物有類似的作用且動物用藥品產量有限，因此鎮痛藥（Gabapentin、Pregabalin、Fentanyl）和抗生素等人類動物用藥品被用作獸藥。仿單標示外成長的伴侶動物數量、診斷技術的進步以及支持性法律規範推動市場的發展。北美引領市場，而亞太地區則展現出強勁的成長潛力。挑戰包括抗生素抗藥性和監管複雜性。

市場促進因素

寵物擁有量增加和慢性疾病

寵物飼養數量的成長趨勢是推動動物用藥品，仿單標示外這些藥物在動物身上已被證實有效。由於人口老化和環境壓力等因素，伴侶動物和牲畜的慢性疾病盛行率不斷上升，這進一步推動了獸用人用藥物的需求。

診斷技術的進步

分子技術和快速就地檢驗等診斷方法的改進，正在提高準確識別動物細菌感染和其他疾病的能力。這些進步使得標靶治療（尤其是抗生素治療）成為可能，確保了治療效果，並推動了對青黴素等已核准用於獸用的人用藥物的需求。準確診斷和治療疾病的能力促進了獸藥領域對人用藥物日益成長的依賴，從而促進了市場擴張。

支持性法規結構

有利的法規，例如允許使用人用藥物治療常見動物疾病的美國聯邦法律，正在推動市場成長。這些法規承認人類與動物之間的基因相似性，並允許使用人類藥物（例如止痛藥和化療藥物）來治療動物的癌症和糖尿病等疾病。支持性政策和獸醫研究資金的增加進一步促進了人用藥物的普及，從而推動了市場成長。

市場限制

健康動物過度使用抗生素加劇了抗生素抗藥性的威脅，損害了治療效果和動物福利。獸藥中人用藥物的仿單標示外使用有許多監管複雜性，包括安全性和劑量問題，這些都阻礙了抗生素的廣泛應用。此外，先進診斷和治療手段的高昂成本也限制了開發中地區的醫療服務可近性。透過負責任地使用抗生素和簡化監管來應對這些挑戰，對於永續發展至關重要。

介紹
北美洲
- 美國
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他
歐洲
- 英國
- 德國
- 法國
- 西班牙
- 其他
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 其他
亞太地區
- 日本
- 中國
- 印度
- 韓國
- 台灣
- 泰國
- 印尼
- 其他

第10章競爭格局及分析

主要企業和策略分析
市場佔有率分析
合併、收購、協議和合作
競爭對手儀表板

第11章：公司簡介

Merck & Co
Zoetis
Boehringer Ingelheim
Elanco Animal Health
Soparfin SCA
Ceva Sante Animale
Virbac SA

第12章調查方法

簡介目錄

Product Code: KSI061612151

The human drugs for veterinary use market is expected to grow from USD 3.704 billion in 2025 to USD 4.240 billion in 2030, at a CAGR of 2.74%.

The global human drugs for veterinary use market is projected to experience robust growth from 2025 to 2030, driven by the rising prevalence of chronic diseases in animals, increasing pet ownership, and the growing trend of using human medications for veterinary purposes. Human drugs, such as painkillers (gabapentin, pregabalin, fentanyl) and antibiotics, are used off-label in veterinary medicine due to their similar effects in animals and the limited production of animal-specific drugs. The market is propelled by the rise in companion animal populations, advancements in diagnostic techniques, and supportive regulatory frameworks. North America leads the market, while Asia-Pacific shows strong growth potential. Challenges include antibiotic resistance and regulatory complexities.

Market Drivers

Rising Pet Ownership and Chronic Diseases

The growing trend of pet ownership is a primary driver, increasing demand for veterinary medicines to manage chronic conditions like heartworm, diabetes, and cancer in companion animals. The rise in pet populations, particularly in developed regions, fuels the need for effective treatments, often met by off-label use of human drugs due to their proven efficacy in animals. The increasing prevalence of chronic diseases in both companion and production animals, driven by factors like aging populations and environmental stressors, further boosts demand for human drugs in veterinary applications.

Advancements in Diagnostic Techniques

Improved diagnostic methods, such as molecular techniques and rapid point-of-care tests, enhance the ability to accurately identify bacterial infections and other conditions in animals. These advancements enable targeted therapies, particularly with antibiotics, ensuring effective treatment and driving demand for human drugs like penicillin, which has been approved for veterinary use. The ability to diagnose and treat conditions with precision supports the growing reliance on human medications in veterinary care, contributing to market expansion.

Supportive Regulatory Frameworks

Favorable regulations, such as U.S. federal laws permitting the use of human medicines for common illnesses in animals, are driving market growth. These regulations recognize the genetic similarities between humans and animals, enabling the use of human drugs like painkillers and chemotherapeutics to treat conditions such as cancer and diabetes in animals. Supportive policies and increased funding for veterinary research further facilitate the adoption of human drugs, boosting market growth.

Market Restraints

The market faces challenges due to the growing threat of antibiotic resistance, driven by the overuse of antibiotics in healthy animals, which compromises treatment efficacy and animal welfare. Regulatory complexities surrounding off-label use of human drugs in veterinary medicine, including safety and dosing concerns, pose barriers to widespread adoption. Additionally, the high cost of advanced diagnostics and treatments may limit access in developing regions. Addressing these challenges through responsible antibiotic use and streamlined regulations will be critical for sustained growth.

Market Segmentation

By Medication Type

The market is segmented into antibiotics, non-steroidal anti-inflammatories, opioid pain relievers, chemotherapeutics, and others. Antibiotics hold a significant share due to the high incidence of bacterial infections in livestock and companion animals, driven by overcrowding and poor hygiene in production facilities. Opioid pain relievers, like fentanyl and buprenorphine, are widely used for pain management in veterinary care.

By End-User

The market includes companion animals and production animals. Companion animals dominate due to rising pet ownership and demand for chronic disease management. Production animals, such as poultry and livestock, are a growing segment, driven by the need for antibiotics and parasiticides to ensure health and productivity.

By Geography

The market is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. North America leads, driven by advanced veterinary facilities, high pet ownership, and supportive regulations. Asia-Pacific is expected to grow rapidly, fueled by increasing pet populations and expanding livestock industries in countries like China and India. Europe, South America, and the Middle East and Africa are emerging markets, supported by growing veterinary care investments.

The human drugs for veterinary use market is set for robust growth from 2025 to 2030, driven by rising pet ownership, advancements in diagnostics, and supportive regulations. Despite challenges like antibiotic resistance and regulatory hurdles, the market's outlook is positive, particularly in North America and Asia-Pacific. Industry players must focus on responsible drug use, innovative diagnostics, and regulatory compliance to capitalize on the growing demand for human drugs in veterinary applications.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2020 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Medication Type

Antibiotics
Non-steroidal anti-inflammatories
Opioid pain relievers
Chemotherapeutics
Others

By Drug Type

Penicillin
Prednisone and Prednisolone
Diazepam
Prozac
Others

By Animal Type

Companion Animals
Cat
Dogs
Livestock Animals
Cattle
Swine
Poultry
Others

By Route of Administration

Oral
Parenteral
Topical

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Italy
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
China
Japan
India
South Korea
Indonesia
Thailand
Taiwan
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL HUMAN DRUGS FOR VETERINARY USE MARKET BY MEDICATION TYPE

5.1. Introduction
5.2. Antibiotics
5.3. Non-steroidal anti-inflammatories
5.4. Opioid pain relievers
5.5. Chemotherapeutics
5.6. Others

6. GLOBAL HUMAN DRUGS FOR VETERINARY USE MARKET BY DRUG TYPE

6.1. Introduction
6.2. Penicillin
6.3. Prednisone and Prednisolone
6.4. Diazepam
6.5. Prozac
6.6. Others

7. GLOBAL HUMAN DRUGS FOR VETERINARY USE MARKET BY ANIMAL TYPE

7.1. Introduction
7.2. Companion Animals
- 7.2.1. Cat
- 7.2.2. Dogs
7.3. Livestock Animals
- 7.3.1. Cattle
- 7.3.2. Swine
- 7.3.3. Poultry
- 7.3.4. Others

8. GLOBAL HUMAN DRUGS FOR VETERINARY USE MARKET BY ROUTE OF ADMINISTRATION

8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Topical

9. GLOBAL HUMAN DRUGS FOR VETERINARY USE MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. USA
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. United Kingdom
- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Spain
- 9.4.5. Others
9.5. Middle East & Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Israel
- 9.5.4. Others
9.6. Asia Pacific
- 9.6.1. Japan
- 9.6.2. China
- 9.6.3. India
- 9.6.4. South Korea
- 9.6.5. Taiwan
- 9.6.6. Thailand
- 9.6.7. Indonesia
- 9.6.8. Others